Menu
KrASIA
News

Chinese biotech startup raises USD 20 million to grow human tissue and organs in pigs

Written by Luna Lin Published on 

Share
Gene-editing technology has come a long way.

Qihan Biotech, a startup focusing on developing so-called xenotransplantation technology, closed a USD 20 million funding round with CMB International and Legendstar, according to 36Kr.

The xenotransplantation technology the firm is working on will use gene-editing to produce human cells, tissues and organs in pigs, which could potentially ease pressure on the current organ shortage.

Every year, more than 300,000 patients in China are waiting for organ transplants, but only a small fraction of patients find compatible organs – in 2017, the country saw 16,000 organ transplant surgeries, according to state news agency Xinhua.

Despite widely seen a solution to organ shortage, xenotransplantation carries potential risks. Among them, the transmission of known or as yet unrecognized xenogeneic infectious agents from animals to human recipients and the possible subsequent transmission to the latter’s close contacts and general public.

Qihan Biotech, a Hangzhou-based company, was set up by Harvard biologist Yang Lunhan in November 2017. Last year, Qihan Biotech finished its Series A funding round with investors including Sequoia China, Arch Venture Partners, Northern Light Venture Capital, Biomatics Capital Partners, and Alta Partners.

Yang is also a co-founder and Chief Scientific Officer of US-based biotech company eGenesis, which works in a similar field.

 

Share

You might like these

  • News

    Thai car rental platform Drivehub gears up for Southeast Asia expansion after seven-digit funding round

    By 

    Stephanie Pearl Li

    28 Jan 2021    03:00 AM

KrASIA InsightsKrASIA Insights

  • Edtech platforms are targeting the labor force with practical classes such as programming, animation, and design.

    Insights

    Indonesian edtech platforms tap practical skills to maintain momentum

    By Ursula Florene

    25 Jan 202104:55 AM

Most PopularMost Popular

See All